183 related articles for article (PubMed ID: 34756628)
1. Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
Van Poppel H; Roobol MJ
Eur Urol; 2022 Jan; 81(1):e23-e24. PubMed ID: 34756628
[No Abstract] [Full Text] [Related]
2. Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
Takahashi T
Eur Urol; 2022 Jan; 81(1):e22. PubMed ID: 34716050
[No Abstract] [Full Text] [Related]
3. Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy.
Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
Eur Urol; 2021 Jul; 80(1):e28-e29. PubMed ID: 33965287
[No Abstract] [Full Text] [Related]
4. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750
[No Abstract] [Full Text] [Related]
5. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
Morrod D
Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
[No Abstract] [Full Text] [Related]
6. Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal Masses.
Campi R; Bertolo R; Minervini A;
Eur Urol; 2022 Feb; 81(2):e46-e47. PubMed ID: 34887115
[No Abstract] [Full Text] [Related]
7. Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74-81.
de Vos II; Remmers S; Roobol MJ
Eur Urol; 2024 May; 85(5):e142. PubMed ID: 38369420
[No Abstract] [Full Text] [Related]
8. Re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy.
Evangelista L; Lopci E
Eur Urol; 2021 Jul; 80(1):e24-e27. PubMed ID: 33947593
[No Abstract] [Full Text] [Related]
9. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
Connolly D; Hutton R; Keane PF
Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
[No Abstract] [Full Text] [Related]
10. Re: Ivo I. de Vos II, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74-81.
Golijanin B; Mega A; Golijanin D
Eur Urol; 2024 May; 85(5):e143-e144. PubMed ID: 38429126
[No Abstract] [Full Text] [Related]
11. Re: Giorgio Gandaglia G, Peter Albers, Per-Anders Abrahamsson, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol 2019;76:142-50.
Froehner M; Koch R; Thomas C
Eur Urol; 2020 Jan; 77(1):e30. PubMed ID: 31836073
[No Abstract] [Full Text] [Related]
12. Re: Jonas Hugosson, Monique J. Roobol, Marianne Månsson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51: Mortality in the Age Group ≥70 yr and the Case of Italy.
Donzelli A; Castelluzzo G; Giudicatti G
Eur Urol; 2020 Mar; 77(3):e70-e71. PubMed ID: 31443958
[No Abstract] [Full Text] [Related]
13. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
[No Abstract] [Full Text] [Related]
14. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
Van Poppel H; Roobol MJ; Chapple CR; Catto JWF; N'Dow J; Sønksen J; Stenzl A; Wirth M
Eur Urol; 2021 Dec; 80(6):703-711. PubMed ID: 34407909
[TBL] [Abstract][Full Text] [Related]
15. Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68.
Morote J
Eur Urol; 2010 Jan; 57(1):e1; author reply e2-3. PubMed ID: 19853371
[No Abstract] [Full Text] [Related]
16. Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
Vickers AJ; Lilja H; Assel M
Eur Urol; 2019 Mar; 75(3):e56. PubMed ID: 30327273
[No Abstract] [Full Text] [Related]
17. Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budäus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:445-46.
Kaplan-Marans E; Zhang TR; Hu JC
Eur Urol; 2023 Dec; 84(6):e151. PubMed ID: 37775359
[No Abstract] [Full Text] [Related]
18. Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
Valerio M; Emberton M; Ahmed HU
Eur Urol; 2019 Feb; 75(2):e21-e22. PubMed ID: 30224194
[No Abstract] [Full Text] [Related]
19. Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2023;83:103-9.
Kim KM; Kim JH; Chung BI
Eur Urol; 2023 May; 83(5):e137-e138. PubMed ID: 36774223
[No Abstract] [Full Text] [Related]
20. Re: Letter to the Editor: Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis. Deepansh Dalela et al. (Urology 2021;148:1-3).
Shah N; Ioffe V
Urology; 2021 Jul; 153():360-361. PubMed ID: 33823173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
